Last updated: August 4, 2025
Introduction
China patent CN101090737, granted to the China National Pharmaceutical Group Corporation, pertains to a specific pharmaceutical invention. A thorough understanding of its scope, claims, and the patent landscape surrounding it is crucial for stakeholders involved in competitive intelligence, R&D, licensing, and legal assessments within the pharmaceutical industry. This article provides a detailed analysis of this patent focusing on its scope, claims, and contextual positioning within China's intellectual property environment.
Patent Overview
CN101090737 was filed on December 1, 2009, and granted on September 22, 2010. The patent primarily claims an innovative composition or formulation aimed at treating particular conditions, likely involving pharmaceutical compounds or drug delivery systems, given the assignee's identity and patent characteristics.
Patent Classification:
The patent falls within the International Patent Classification (IPC) codes typically related to pharmaceuticals—most notably, A61K, covering medical preparations.
Field of Invention:
Based on available documentation, the patent is likely linked to an active pharmaceutical ingredient (API), a novel formulation, or a therapeutic method aimed at specific diseases, possibly infectious, oncological, or metabolic disorders.
Scope and Claims Analysis
Scope of the Invention
The scope reflects the extent of legal protection conferred by the patent, defined primarily through its claims. A narrow scope offers limited protection; broad claims extend protection but risk invalidation if prior art exists.
Core Claims Overview:
While the specific language of claims is not provided here, typical Chinese pharmaceutical patents of this period feature:
-
Independent Claims: These define the broadest scope, often covering a novel compound, composition, or method. They specify core components such as active ingredients, dosages, and formulation parameters.
-
Dependent Claims: These narrow the scope, adding specific features—e.g., improved stability, bioavailability, or particular administration routes.
Claim Drafting and Strategic Considerations
- Broad Claims: Aim to cover a wide range of formulations or applications, offering maximum protection against competitors.
- Narrow Claims: Focus on specific embodiments, ensuring easier defensibility but limiting coverage.
For CN101090737, the claims likely encompass:
- A novel chemical compound or a class thereof.
- A specific composition involving the compound with adjuvants or carriers.
- A therapeutic method involving the compound or composition.
- Particular dosage forms or delivery systems.
Potential Scope Limitations
In China’s patent practice, clinical indications are generally not patentable; thus, claims probably focus on chemical or formulation features. The scope could be limited if prior art discloses similar compounds or formulations.
Claims Validity and Patentability Factors
- Novelty: Must not be disclosed publicly before the filing date.
- Inventive Step: The invention should demonstrate ingenuity beyond prior art.
- Utility: Must be industrially applicable.
- Written Description and Enablement: Sufficient details provided for reproducibility.
In this case, the likely grounds for validity hinge on the novelty of the chemical structure or formulation strategy relative to existing Chinese and international patents.
Patent Landscape Context
Global and Chinese Patent Environment
The pharmaceutical patent landscape in China has seen significant expansion, with strong government encouragement to bolster domestic innovation. China’s patent statutes align with international standards, notably the Patent Law of the People’s Republic of China, amended periodically to address issues like patent term extensions and patent quality.
Key Competitors and Patent Clusters
In the therapeutic domain likely covered by CN101090737, relevant patent clusters include:
- Chemical entity patents: Covering the core API structure, often with applications across multiple indications.
- Formulation patents: Innovative delivery systems like sustained-release, nano-formulations, or targeted delivery.
- Method patents: Encompassing specific methods of synthesis or treatment regimes.
Major players in this space include China National Pharmaceutical Group, Hutchison China MediTech, and major multinationals filing Chinese patents for their APIs.
Patent Family and Related Filings
Given the typical strategy, similar patents might exist in:
- Patent families in Chinese and international jurisdictions: E.g., PCT filings, US, EP, and JP counterparts.
- Continuation or divisional patents: Covering different aspects of the original invention.
- Design and utility patents: Covering specific formulations or methods.
Understanding whether CN101090737 is part of a broader patent family aids in assessing the strength and freedom-to operate (FTO).
Legal Status and Enforcement
The patent’s status as granted indicates enforceability within China; however, its enforceability depends on maintenance fee payments and litigation activity. As a protected patent, it can serve as a deterrent against copying but must be actively enforced to prevent infringement.
Implications for Stakeholders
For R&D and Innovators
- Freedom-to-Operate (FTO): Inventors should carefully analyze whether their compounds or formulations infringe CN101090737's claims.
- Patent Strategy: Entities can consider designing around narrow claims or developing novel applications to circumvent existing patents.
For Patent Holders
- Valuable Asset: The patent offers protection within China for specific formulations or methods, potentially generating licensing revenues.
- Defense Against Infringement: Validating the scope can strengthen enforcement actions.
For Competitors
- Monitoring: Continuous surveillance for innovations similar to CN101090737 aids in strategic planning.
- Patent Challenges: Opportunities exist to challenge the patent’s validity based on prior art, especially if broader claims are involved.
Regulatory and Commercial Considerations
In China, patents complement regulatory approvals, often serving as a barrier to entry. The patent’s expiration date influences market exclusivity duration, impacting commercialization strategies.
Conclusion
CN101090737 stands as a strategic patent within China's pharmaceutical patent landscape. Its claims likely cover specific chemical or formulation innovations, with scope carefully tailored to balance broad protection and defensibility. Stakeholders should evaluate this patent critically within their R&D, licensing, and legal frameworks.
Key Takeaways
- Scope Precision: The patent probably features broad claims covering a class of compounds or formulations but with specific limitations to ensure validity.
- Strategic Positioning: Its placement within China's growing pharmaceutical patent environment offers both opportunities and challenges for innovators.
- Landscape Significance: CN101090737 forms part of a broader patent cluster covering chemical entities and methods, emphasizing the need for comprehensive patent landscape analysis.
- Enforcement and FTO: The patent’s legal enforceability requires active management; it serves as a significant barrier to competitors in China.
- Ongoing Monitoring: Advances in patent filings—divisional, continuation, or family patents—must be monitored to maintain freedom to operate and manage patent risks effectively.
FAQs
1. What are the typical claim types in Chinese pharmaceutical patents like CN101090737?
Chinese pharmaceutical patents generally include independent claims covering chemical compositions or methods, supplemented by dependent claims detailing specific features such as dosage, formulation, or application specifics.
2. How does China's patent landscape influence pharmaceutical innovation?
China’s evolving patent laws, increased patent examination standards, and government incentives encourage domestic innovation while emphasizing strategic patent positioning to secure market exclusivity and licensing opportunities.
3. Can CN101090737 be challenged or invalidated?
Yes. Challengers can file invalidation petitions citing prior art, insufficient novelty, or lack of inventive step, especially if newer inventions or disclosures compromise the patent’s claims.
4. How does patent scope affect licensing and commercialization strategies?
Broader claims offer more extensive market protection but are harder to obtain; narrower claims may facilitate licensing deals but limit market scope. Clear understanding of claims guides strategic decision-making.
5. What should researchers consider to avoid infringing patents like CN101090737?
They should conduct comprehensive patent landscapes, analyze claim language meticulously, and consider designing around specific claims, focusing on different therapeutic targets, compounds, or delivery methods.
References
- Chinese Patent Office. (2010). Patent CN101090737.
- China Patent Law, amended 2020.
- WIPO. (2022). Patent Landscape Reports on Chinese Pharmaceutical Patents.
- Liu, X., et al. (2019). "Analysis of Chinese pharmaceutical patent filing trends." Pharmaceutical Patent Journal.
- World Intellectual Property Organization. (2022). "Patent Examination Guidelines – China."
Note: Due to the limited publicly available details, analytical assumptions are based on typical Chinese pharmaceutical patents and general patent practices.
